Jack Raisanen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jack Raisanen has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Charles L. White
University of Texas Southwestern Medical Center
4 shared publications Kimmo J. Hatanpaa
Department of Pathology, The University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA
4 shared publications- Maria-Magdalena Georgescu
NeuroMarkers PLLC, Houston, USA
3 shared publications Bruce E. Mickey
2 shared publications- Kimmo J. Hatanpaa
Department of Pathology, University of Texas Southwestern Medical Center, Dallas, USA
2 shared publications - Aaron R. Plitt
Department of Neurological Surgery, Southwestern Medical Center, University of Texas, Dallas, Texas, United States
1 shared publication
Latest Publications
- Open Access
Mutation Status and Epithelial Differentiation Stratify Recurrence Risk in Chordoid Meningioma—A Multicenter Study with High Prognostic Relevance
Chordoid meningioma is a rare WHO grade II histologic variant. Its molecular alterations or their impact on patient risk stratification have not been fully explored. We performed a multicenter, clinical, histological, and genomic analysis of chordoid meningiomas from 30 patients (34 tumors), representing the largest integrated study to date. By NHERF1 microlumen immunohistochemical detection, three epithelial differentiation (ED) groups emerged: #1/fibroblastic-like, #2/epithelial-poorly-differentiated and #3/epithelial-well-differentiated. These ED groups correlated with tumor location and genetic profiling, with NF2 and chromatin remodeling gene mutations clustering in ED group #2, and TRAF7 mutations segregating in ED group #3. Mutations in LRP1B were found in the largest number of cases (36%) across ED groups #2 and #3. Pathogenic ATM and VHL germline mutations occurred in ED group #3 patients, conferring an aggressive or benign course, respectively. The recurrence rate significantly correlated with mutations in NF2, as single gene, and with mutations in chromatin remodeling and DNA damage response genes, as groups. The recurrence rate was very high in ED group #2, moderate in ED group #3, and absent in ED group #1. This study proposes guidelines for tumor recurrence risk stratification and practical considerations for patient management.
Open AccessMutation Status and Epithelial Differentiation Stratify Recurrence Risk in Chordoid Meningioma—A Multicenter Study with High Prognostic Relevance
Chordoid meningioma is a rare WHO grade II histologic variant. Its molecular alterations or their impact on patient risk stratification have not been fully explored. We performed a multicenter, clinical, histological, and genomic analysis of chordoid meningiomas from 30 patients (34 tumors), representing the largest integrated study to date. By NHERF1 microlumen immunohistochemical detection, three epithelial differentiation (ED) groups emerged: #1/fibroblastic-like, #2/epithelial-poorly-differentiated and #3/epithelial-well-differentiated. These ED groups correlated with tumor location and genetic profiling, with NF2 and chromatin remodeling gene mutations clustering in ED group #2, and TRAF7 mutations segregating in ED group #3. Mutations in LRP1B were found in the largest number of cases (36%) across ED groups #2 and #3. Pathogenic ATM and VHL germline mutations occurred in ED group #3 patients, conferring an aggressive or benign course, respectively. The recurrence rate significantly correlated with mutations in NF2, as single gene, and with mutations in chromatin remodeling and DNA damage response genes, as groups. The recurrence rate was very high in ED group #2, moderate in ED group #3, and absent in ED group #1. This study proposes guidelines for tumor recurrence risk stratification and practical considerations for patient management.
- Open Access
- 26 July 2019
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 10, 148
Intracranial anaplastic hemangiopericytoma presenting with simultaneous extra-cranial metastases: A case report and review of the literature.
Intracranial solitary fibrous tumor/hemangiopericytoma (SFT/HPC) is a rare mesenchymal tumor with a propensity to recur and metastasize extracranially years after treatment. Accordingly, there are no reported cases of a patient presenting with a simultaneous intracranial primary and extracranial metastases. We present the case of a patient presenting with an intracranial SFT/HPC and simultaneous liver metastases and propose a treatment paradigm. A 74-year-old male smoker presented with confusion. An MRI of the brain revealed a heterogeneously enhancing left frontal extra-axial mass. Systemic workup revealed multiple small liver lesions concerning for metastases. The patient underwent gross total resection (GTR) of the intracranial lesion with adjuvant CyberKnife stereotactic radiotherapy to the resection cavity. Pathology was consistent with a WHO Grade III SFT/HPC (previously known as anaplastic HPC). The liver lesions were biopsied and confirmed to be metastases. They were subsequently treated with stereotactic body radiation therapy, temozolomide, and bevacizumab. Eighteen months postoperatively, the patient is alive with no evidence of intracranial malignancy and regression of the hepatic lesions. Several studies support GTR and adjuvant radiotherapy to treat intracranial SFT/HPC. The role of adjuvant chemotherapy is less clear. Metastatic disease is typically detected several years after the initial diagnosis, and there is no consensus regarding the optimal treatment strategy. We propose that the rare presentation of intracranial SFT/HPC with simultaneous extracranial metastases should be treated in a multidisciplinary fashion with surgical resection, adjuvant radiotherapy, and chemotherapy.
- 26 July 2019
- Published by Scientific Scholar in Surgical Neurology International
- Vol. 10, 148
Open AccessIntracranial anaplastic hemangiopericytoma presenting with simultaneous extra-cranial metastases: A case report and review of the literature.
Intracranial solitary fibrous tumor/hemangiopericytoma (SFT/HPC) is a rare mesenchymal tumor with a propensity to recur and metastasize extracranially years after treatment. Accordingly, there are no reported cases of a patient presenting with a simultaneous intracranial primary and extracranial metastases. We present the case of a patient presenting with an intracranial SFT/HPC and simultaneous liver metastases and propose a treatment paradigm. A 74-year-old male smoker presented with confusion. An MRI of the brain revealed a heterogeneously enhancing left frontal extra-axial mass. Systemic workup revealed multiple small liver lesions concerning for metastases. The patient underwent gross total resection (GTR) of the intracranial lesion with adjuvant CyberKnife stereotactic radiotherapy to the resection cavity. Pathology was consistent with a WHO Grade III SFT/HPC (previously known as anaplastic HPC). The liver lesions were biopsied and confirmed to be metastases. They were subsequently treated with stereotactic body radiation therapy, temozolomide, and bevacizumab. Eighteen months postoperatively, the patient is alive with no evidence of intracranial malignancy and regression of the hepatic lesions. Several studies support GTR and adjuvant radiotherapy to treat intracranial SFT/HPC. The role of adjuvant chemotherapy is less clear. Metastatic disease is typically detected several years after the initial diagnosis, and there is no consensus regarding the optimal treatment strategy. We propose that the rare presentation of intracranial SFT/HPC with simultaneous extracranial metastases should be treated in a multidisciplinary fashion with surgical resection, adjuvant radiotherapy, and chemotherapy.
- 1 May 2017
- Published by Dustri-Verlag Dr. Karl Feistle in Clinical Neuropathology
- Vol. 36 (5) , 114-120
Unusual skull tumors with psammomatoid bodies: a diagnostic challenge
We describe a series of three diagnostically challenging, histologically similar fibro-osseous skull masses. The cases were identified in our archives among 50,000 neuropathology specimens. A comprehensive review of the histological, immunohistochemical, ultrastructural, and imaging features as well as the clinical outcome was performed. The routine histology was similar in all 3 cases and showed spindle cell proliferations with frequent calcospheres or psammomatoid bodies. There was no evidence of an underlying subdural component. Immunohistochemistry for the meningioma markers EMA and SSTR2A raised the possibility of intraosseous meningioma, as all 3 lesions were convincingly positive for epithelial membrane antigen (EMA) and 1 lesion was convincingly positive for the somatostatin receptor subtype 2A (SSTR2A); weak, questionable positivity for SSTR2 was present in the remaining 2 cases. In addition, electron microscopy was available in 1 case and showed features consistent with meningioma. Overall, the findings were most consistent with intraosseous meningioma. Primary intraosseous meningiomas are rare lesions that may present a diagnostic challenge. It is important to consider meningiomas in the differential diagnosis, as extradural meningiomas are associated with an increased risk of recurrence and may occasionally undergo malignant transformation. .
- 1 May 2017
- Published by Dustri-Verlag Dr. Karl Feistle in Clinical Neuropathology
- Vol. 36 (5) , 114-120
Unusual skull tumors with psammomatoid bodies: a diagnostic challenge
We describe a series of three diagnostically challenging, histologically similar fibro-osseous skull masses. The cases were identified in our archives among 50,000 neuropathology specimens. A comprehensive review of the histological, immunohistochemical, ultrastructural, and imaging features as well as the clinical outcome was performed. The routine histology was similar in all 3 cases and showed spindle cell proliferations with frequent calcospheres or psammomatoid bodies. There was no evidence of an underlying subdural component. Immunohistochemistry for the meningioma markers EMA and SSTR2A raised the possibility of intraosseous meningioma, as all 3 lesions were convincingly positive for epithelial membrane antigen (EMA) and 1 lesion was convincingly positive for the somatostatin receptor subtype 2A (SSTR2A); weak, questionable positivity for SSTR2 was present in the remaining 2 cases. In addition, electron microscopy was available in 1 case and showed features consistent with meningioma. Overall, the findings were most consistent with intraosseous meningioma. Primary intraosseous meningiomas are rare lesions that may present a diagnostic challenge. It is important to consider meningiomas in the differential diagnosis, as extradural meningiomas are associated with an increased risk of recurrence and may occasionally undergo malignant transformation. .
- Open Access
- 27 May 2016
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 4 (1) , 55
NHERF1/EBP50 and NF2 as diagnostic markers for choroid plexus tumors
The adaptor protein NHERF1 (Na/H exchanger-3 regulatory factor-1) and its associated ezrin-radixin-moesin-merlin/neurofibromin-2 (ERM-NF2) family proteins are required for epithelial morphogenesis and have been implicated in cancer progression. NHERF1 is expressed in ependymal cells and constitutes a highly sensitive diagnostic marker for ependymoma, where it labels membrane polarity structures. Since NHERF1 and ERM-NF2 proteins show polarized expression in choroid plexus (CP) cells, we tested their diagnostic utility in CP neoplasms. NHERF1 immunohistochemistry in 43 adult and pediatric tumors with papillary morphology revealed strong apical plasma membrane staining in CP papilloma (WHO grade I) and cytoplasmic expression in CP carcinoma (WHO grade III). Ezrin and moesin showed similar but less distinctive staining. NHERF1 also labeled papillary tumors of the pineal region in a microlumen and focal apical membrane pattern, suggestive of a transitional morphology between CP papilloma and ependymoma. CP tumors of all grades could be differentiated from metastatic carcinomas with papillary architecture by NF2, which showed polarized membranous staining in CP tumors. NHERF1 and NF2 immunohistochemistry showed enhanced sensitivity and specificity for CP tumors compared to commonly used markers, including cytokeratins and Kir7.1, emerging as reliable diagnostic tools for the differential diagnosis of papillary tumors of the central nervous system.
- 27 May 2016
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 4 (1) , 55
Open AccessNHERF1/EBP50 and NF2 as diagnostic markers for choroid plexus tumors
The adaptor protein NHERF1 (Na/H exchanger-3 regulatory factor-1) and its associated ezrin-radixin-moesin-merlin/neurofibromin-2 (ERM-NF2) family proteins are required for epithelial morphogenesis and have been implicated in cancer progression. NHERF1 is expressed in ependymal cells and constitutes a highly sensitive diagnostic marker for ependymoma, where it labels membrane polarity structures. Since NHERF1 and ERM-NF2 proteins show polarized expression in choroid plexus (CP) cells, we tested their diagnostic utility in CP neoplasms. NHERF1 immunohistochemistry in 43 adult and pediatric tumors with papillary morphology revealed strong apical plasma membrane staining in CP papilloma (WHO grade I) and cytoplasmic expression in CP carcinoma (WHO grade III). Ezrin and moesin showed similar but less distinctive staining. NHERF1 also labeled papillary tumors of the pineal region in a microlumen and focal apical membrane pattern, suggestive of a transitional morphology between CP papilloma and ependymoma. CP tumors of all grades could be differentiated from metastatic carcinomas with papillary architecture by NF2, which showed polarized membranous staining in CP tumors. NHERF1 and NF2 immunohistochemistry showed enhanced sensitivity and specificity for CP tumors compared to commonly used markers, including cytokeratins and Kir7.1, emerging as reliable diagnostic tools for the differential diagnosis of papillary tumors of the central nervous system.
- Open Access
- 8 March 2015
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 3 (1) , 11
NHERF1/EBP50 is an organizer of polarity structures and a diagnostic marker in ependymoma
NHERF1/EBP50, an adaptor protein required for epithelial morphogenesis, has been implicated in the progression of various human malignancies. NHERF1-deficient mice have intestinal brush border structural defects and we report here that they also have disorganized ependymal cilia with development of non-obstructive hydrocephalus. Examination of mouse and human brain tissues revealed highest NHERF1 expression at the apical plasma membrane of ependymal cells. In ependymal tumors, NHERF1 expression was retained in polarized membrane structures, such as microlumens, rosettes and canals, where it co-localized with some of its ligands, such as moesin and PTEN. Analysis of a comprehensive panel of 113 tumors showed robust NHERF1 labeling of microlumens in 100% of ependymomas, subependymomas, and pediatric anaplastic ependymomas, and in 67% of adult anaplastic ependymomas. NHERF1 staining was present in 35% of ependymoma cases that lacked reactivity for EMA, the routine immunohistochemical marker used for ependymoma diagnosis. NHERF1 labeling of microlumens was either absent or rarely seen in other types of brain tumors analyzed, denoting NHERF1 as a reliable diagnostic marker of ependymal tumors. Anaplastic foci and a subset of adult anaplastic ependymomas showed complete absence of NHERF1-labeled polarity structures, consistent with a loss of differentiation in these aggressive tumors. These data highlight a role for NHERF1 in ependymal morphogenesis with direct application to the diagnosis of ependymal tumors.
- 8 March 2015
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 3 (1) , 11
Open AccessNHERF1/EBP50 is an organizer of polarity structures and a diagnostic marker in ependymoma
NHERF1/EBP50, an adaptor protein required for epithelial morphogenesis, has been implicated in the progression of various human malignancies. NHERF1-deficient mice have intestinal brush border structural defects and we report here that they also have disorganized ependymal cilia with development of non-obstructive hydrocephalus. Examination of mouse and human brain tissues revealed highest NHERF1 expression at the apical plasma membrane of ependymal cells. In ependymal tumors, NHERF1 expression was retained in polarized membrane structures, such as microlumens, rosettes and canals, where it co-localized with some of its ligands, such as moesin and PTEN. Analysis of a comprehensive panel of 113 tumors showed robust NHERF1 labeling of microlumens in 100% of ependymomas, subependymomas, and pediatric anaplastic ependymomas, and in 67% of adult anaplastic ependymomas. NHERF1 staining was present in 35% of ependymoma cases that lacked reactivity for EMA, the routine immunohistochemical marker used for ependymoma diagnosis. NHERF1 labeling of microlumens was either absent or rarely seen in other types of brain tumors analyzed, denoting NHERF1 as a reliable diagnostic marker of ependymal tumors. Anaplastic foci and a subset of adult anaplastic ependymomas showed complete absence of NHERF1-labeled polarity structures, consistent with a loss of differentiation in these aggressive tumors. These data highlight a role for NHERF1 in ependymal morphogenesis with direct application to the diagnosis of ependymal tumors.
- 17 February 2014
- Published by Georg Thieme Verlag KG in Journal of Neurological Surgery Part B: Skull Base
- Vol. 75 (S 01) , A090
The Far Lateral Approach for Foramen Magnum Meningiomas
Background: Foramen Magnum (FM) meningiomas pose significant challenges to the treating neurosurgeon. The insidious onset of symptoms often contributes to a delayed diagnosis and a relatively large size at the time of presentation. Symptoms are often produced by compression of surrounding structures within a critically confined space. Posterior and posterolateral FM meningiomas can be safely resected via standard midline suboccipital approach. Controversy still exits regarding the optimal management of anterior or anterolateral lesions. Objective: describe a single institution experience with the surgical management of FM meningiomas, with emphasis on the far lateral approach and its variations. Clinical presentation, imaging findings, pathologic features, recurrence rates and functional outcome are discussed. Methods: retrospective review of prospectively collected data was performed. All patients with ventral or ventrolateral FM meningiomas, presenting to UT Southwestern Medical Center between 2000 and 2011, were identified. Preoperative clinical signs/symptoms, duration of symptoms, neurological exam and radiographic findings on MRI were analyzed. Intraoperative technical nuances and surgical variations were individually identified. Functional outcome was assessed at the time of hospital discharge and of last ambulatory visit. Results: 30 patients with FM meningiomas treated surgically were identified. Mean age at time of surgery was 55.6 + 12.2 years. Majority of patients were female (71.4%). Headaches (42.6%) and hemibody sensory deficits (39.3%) were the most common presenting symptoms, followed by hemiparesis (28.6%), neck pain (21.4%) and gait disturbances (21.4%). The incidence of symptomatic cranial nerve deficits preoperatively was low (14.3%). The elapsed time between onset of symptoms and initial diagnosis was 10.3 months. The transcondylar variant was utilized in 89.3% of the cases. Transposition of the VA was done in 10 patients. Gross total resection was achieved in 85.7% of the patients. One patient underwent adjuvant Cyber Knife radiosurgery to a small residual tumor adherent to the VA. There were no recurrences and none of the four patients with subtotal resection have demonstrated tumor growth on serial imaging follow-up. Histologically, 90% of the FM meningiomas were WHO Grade I, with meningothelial the most common subtype. One patient had persistent low postoperative KPS and was dependent for ADLs. Twenty two patients had complete resolution of their preoperative symptoms within the initial eight postoperative weeks. No patients had deterioration of neurological function postoperatively. Cerebrospinal fluid leak occurred in 10% of the patients and resolved with temporary lumbar CSF drainage. Tracheostomy and gastrostomy tube placement were necessary in two (6.6%) and three patients (10%), respectively. There was no postoperative mortality at last follow-up. Conclusions: FM Meningiomas are rare, surgically challenging lesions. The far lateral approach is a versatile technique that provides excellent exposure to meningiomas located at the lower clivus and cervicomedullary junction. Advancement in microsurgical techniques and application of modern Skull Base Surgery principles have positively influenced the outcome while providing acceptable rates of morbidity and mortality.
- 17 February 2014
- Published by Georg Thieme Verlag KG in Journal of Neurological Surgery Part B: Skull Base
- Vol. 75 (S 01) , A090
The Far Lateral Approach for Foramen Magnum Meningiomas
Background: Foramen Magnum (FM) meningiomas pose significant challenges to the treating neurosurgeon. The insidious onset of symptoms often contributes to a delayed diagnosis and a relatively large size at the time of presentation. Symptoms are often produced by compression of surrounding structures within a critically confined space. Posterior and posterolateral FM meningiomas can be safely resected via standard midline suboccipital approach. Controversy still exits regarding the optimal management of anterior or anterolateral lesions. Objective: describe a single institution experience with the surgical management of FM meningiomas, with emphasis on the far lateral approach and its variations. Clinical presentation, imaging findings, pathologic features, recurrence rates and functional outcome are discussed. Methods: retrospective review of prospectively collected data was performed. All patients with ventral or ventrolateral FM meningiomas, presenting to UT Southwestern Medical Center between 2000 and 2011, were identified. Preoperative clinical signs/symptoms, duration of symptoms, neurological exam and radiographic findings on MRI were analyzed. Intraoperative technical nuances and surgical variations were individually identified. Functional outcome was assessed at the time of hospital discharge and of last ambulatory visit. Results: 30 patients with FM meningiomas treated surgically were identified. Mean age at time of surgery was 55.6 + 12.2 years. Majority of patients were female (71.4%). Headaches (42.6%) and hemibody sensory deficits (39.3%) were the most common presenting symptoms, followed by hemiparesis (28.6%), neck pain (21.4%) and gait disturbances (21.4%). The incidence of symptomatic cranial nerve deficits preoperatively was low (14.3%). The elapsed time between onset of symptoms and initial diagnosis was 10.3 months. The transcondylar variant was utilized in 89.3% of the cases. Transposition of the VA was done in 10 patients. Gross total resection was achieved in 85.7% of the patients. One patient underwent adjuvant Cyber Knife radiosurgery to a small residual tumor adherent to the VA. There were no recurrences and none of the four patients with subtotal resection have demonstrated tumor growth on serial imaging follow-up. Histologically, 90% of the FM meningiomas were WHO Grade I, with meningothelial the most common subtype. One patient had persistent low postoperative KPS and was dependent for ADLs. Twenty two patients had complete resolution of their preoperative symptoms within the initial eight postoperative weeks. No patients had deterioration of neurological function postoperatively. Cerebrospinal fluid leak occurred in 10% of the patients and resolved with temporary lumbar CSF drainage. Tracheostomy and gastrostomy tube placement were necessary in two (6.6%) and three patients (10%), respectively. There was no postoperative mortality at last follow-up. Conclusions: FM Meningiomas are rare, surgically challenging lesions. The far lateral approach is a versatile technique that provides excellent exposure to meningiomas located at the lower clivus and cervicomedullary junction. Advancement in microsurgical techniques and application of modern Skull Base Surgery principles have positively influenced the outcome while providing acceptable rates of morbidity and mortality.
- 5 April 2006
- Published by Wiley in Brain Pathology
- Vol. 15 (1) , 23-28
Chromosome 22q Deletions in Atypical Teratoid/Rhabdoid Tumors in Adults
Atypical teratoid/rhabdoid tumors (AT/RTs) are rare, malignant brain tumors that usually occur in the posterior fossa. Both AT/RT and the analogous tumor outside the brain, malignant rhabdoid tumor, share a polyphenotypic immunoprofile and frequent 22q deletions with inactivation of the INI1/hSNF5 gene. Reports, so far, indicate that AT/RTs occur almost exclusively in children, most of whom are 5‐years‐old or less. The rarity of the tumor and the polyphenotypic immunoprofile, characterized by antigen expression that is often patchy, make diagnosis in adults difficult and controversial. We describe three AT/RTs in adults in which the diagnoses were supported by detection of 22q11.2 deletions, INI1 mutation and/or loss of INI1 protein expression. Two patients were female, ages 20 and 31 and one was male, age 45. Two tumors occurred in the sella or sellar region and one in the cerebellum. In all cases, fluorescence in situ hybridization with probes to the BCR (22q11.2) and NF2 (22q12) regions of chromosome 22 revealed single copy deletions of BCR with normal dosages of NF2 and, in all cases, immunohistochemistry demonstrated loss of INI1 protein expression. In one case, a single base pair deletion was detected in the INI1/hSNF5 gene. These molecular findings confirm the occurrence of AT/RTs in adults. Although rare, AT/RT should be considered in the differential diagnosis of poorly differentiated intracranial tumors in adults.
- 5 April 2006
- Published by Wiley in Brain Pathology
- Vol. 15 (1) , 23-28
Chromosome 22q Deletions in Atypical Teratoid/Rhabdoid Tumors in Adults
Atypical teratoid/rhabdoid tumors (AT/RTs) are rare, malignant brain tumors that usually occur in the posterior fossa. Both AT/RT and the analogous tumor outside the brain, malignant rhabdoid tumor, share a polyphenotypic immunoprofile and frequent 22q deletions with inactivation of the INI1/hSNF5 gene. Reports, so far, indicate that AT/RTs occur almost exclusively in children, most of whom are 5‐years‐old or less. The rarity of the tumor and the polyphenotypic immunoprofile, characterized by antigen expression that is often patchy, make diagnosis in adults difficult and controversial. We describe three AT/RTs in adults in which the diagnoses were supported by detection of 22q11.2 deletions, INI1 mutation and/or loss of INI1 protein expression. Two patients were female, ages 20 and 31 and one was male, age 45. Two tumors occurred in the sella or sellar region and one in the cerebellum. In all cases, fluorescence in situ hybridization with probes to the BCR (22q11.2) and NF2 (22q12) regions of chromosome 22 revealed single copy deletions of BCR with normal dosages of NF2 and, in all cases, immunohistochemistry demonstrated loss of INI1 protein expression. In one case, a single base pair deletion was detected in the INI1/hSNF5 gene. These molecular findings confirm the occurrence of AT/RTs in adults. Although rare, AT/RT should be considered in the differential diagnosis of poorly differentiated intracranial tumors in adults.
- 28 June 2004
- Published by Wiley in Diagnostic Cytopathology
- Vol. 31 (1) , 60-63
Atypical teratoid/rhabdoid tumor: Cytology and differential diagnosis in adults
Atypical teratoid/rhabdoid tumors (AT/RTs) are malignant intracranial neoplasms that usually occur in the posterior fossa of children. They are characterized by cells with paranuclear rhabdoid inclusions, a mesenchymal and epithelial immunohistochemical profile, and 22q deletions with inactivation of the INI1/hSNF5 gene. Although they usually occur in young children, AT/RTs are being recognized in adults with increasing frequency. We report the cytologic features of an AT/RT from the cerebellum of a 45‐year‐old man and discuss the differential diagnosis in adults. Diagn. Cytopathol. 2004;31:60–63.
- 28 June 2004
- Published by Wiley in Diagnostic Cytopathology
- Vol. 31 (1) , 60-63
Atypical teratoid/rhabdoid tumor: Cytology and differential diagnosis in adults
Atypical teratoid/rhabdoid tumors (AT/RTs) are malignant intracranial neoplasms that usually occur in the posterior fossa of children. They are characterized by cells with paranuclear rhabdoid inclusions, a mesenchymal and epithelial immunohistochemical profile, and 22q deletions with inactivation of the INI1/hSNF5 gene. Although they usually occur in young children, AT/RTs are being recognized in adults with increasing frequency. We report the cytologic features of an AT/RT from the cerebellum of a 45‐year‐old man and discuss the differential diagnosis in adults. Diagn. Cytopathol. 2004;31:60–63.
- 7 June 2003
- Vol. 47 (3) , 518-20
Cytology of subependymoma.